FindTrial
Sign In

Efficacy and safety of vasopressor use in adult patients with traumatic hemorrhagic shock: systematic review

Efficacy and safety of vasopressor use in adult patients with traumatic hemorrhagic shock: systematic review - Efficacy and safety of vasopressor use in adult patients with traumatic hemorrhagic shock: systematic review

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000058760
Enrollment
Unknown
Registered
2025-08-30
Start date
2025-08-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult patients with traumatic hemorrhagic shock

Interventions

None listed

Sponsors

Kyoto University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: See the attached protocol

Exclusion criteria

Exclusion criteria: See the attached protocol

Design outcomes

Primary

MeasureTime frame
Primary outcomes 1. All-cause mortality at the longest follow-up available. 2. Health-related quality of life (HRQoL), when reported. 3. Short-term mortality, defined as death within 24 hours, 7 days, or 30 days from injury or randomization.—

Secondary

MeasureTime frame
Secondary outcomes 4. Length of ICU stay 5. Length of hospital stay 6. Occurrence of organ dysfunction, including multiple organ dysfunction syndrome (MODS) according to definitions used in the included studies. 7. Adverse events related to vasopressor use, such as arrhythmia, myocardial infarction, digital or mesenteric ischemia, acute kidney injury.—

Countries

Japan

Contacts

Public ContactYohei Okaad

See the attached protocol See the attached protocol

yokada-kyf@umin.ac.jp+819043018831

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026